Story
Novo Nordisk Sues Eli Lilly, Alleging False Advertising for Weight-Loss Drugs

Novo Nordisk has filed a lawsuit against its primary competitor, Eli Lilly, alleging the U.S. drugmaker is using false and misleading advertising to promote its popular weight-loss and diabetes drugs. The suit, filed in a U.S. federal court, escalates the intense rivalry between the two pharmaceutical giants in the multi-billion dollar obesity drug market.
Details of the Lawsuit
The complaint, filed on Tuesday in the U.S. District Court in New Jersey, claims that Eli Lilly's nationwide advertising campaigns for Zepbound and Mounjaro violate federal and state laws, including the Lanham Act, which governs false advertising and unfair competition.
Novo Nordisk alleges that Lilly's advertisements create a deceptive impression of superior efficacy. The core of the claim is that Lilly compares the highest approved doses of its medications against lower, less effective doses of Novo's competing drugs, Wegovy and Ozempic, while omitting data from Novo's newer, higher-dose options.
A Battle Over Dosing and Data
According to Novo's general counsel, John Kuckelman, Lilly's ads compare weight-loss results of approximately 50 pounds for Zepbound with about 33 pounds for Wegovy. Novo argues this is an unfair comparison.
AdKuckelman stated that separate late-stage trials of the highest approved doses of each drug showed much more comparable results: an average weight loss of about 48 pounds for Zepbound and 47 pounds for Wegovy. The lawsuit emphasizes that no head-to-head clinical trial has directly compared the highest doses of the two medicines.
Legal Demands and Market Context
The Danish pharmaceutical company is seeking a court order that would require Lilly to withdraw the advertisements and fund a corrective ad campaign. Novo Nordisk also stated it plans to seek a preliminary injunction if Lilly does not voluntarily comply.
This legal action follows a cease-and-desist letter Novo sent to Lilly in April, after the U.S. approval of a higher 7.2-milligram dose of Wegovy. According to the complaint, Lilly did not formally respond but instead added a disclaimer to its ads that Novo's counsel described as "inadequate." The lawsuit marks a significant new front in the fierce competition for dominance in the rapidly expanding market for GLP-1 therapies.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.